Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fred Hutchinson Cancer Center
With
Burroughs Wellcome
National Institutes of Health (NIH)
Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT) recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective prevention strategy has not been established.
77 marrow allograft recipients at risk for VZV reactivation were randomized to oral acyclovir 800 mg twice daily or placebo given from day 30 until day 365 and were followed for toxicity and clinical evidence of herpes zoster infection.
Age
10–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
10 years or older
Both sex (male or female)
Allogeneic transplant patient for hematologic malignancy or aplastic anemia
You may not be if
Previous intolerance to acyclovir
Patients who are unavailable for follow-up
Patients in whom drug compliance may be a problem
Evidence of active VZV infection
VZV infection in the initial 1 month after transplant
Pregnant women, lactating women, or those not using adequate contraception
Creatinine \> 3.0 mg/dl.
Clareo Health | Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
